Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 2 completed trials

    Completion Rate
    100%(2/2)
    Active Trials
    0(0%)
    Results Posted
    0%(0 trials)

    Phase Distribution

    Phase 2/3
    2
    67%

    Phase Distribution

    0

    Early Stage

    2

    Mid Stage

    0

    Late Stage

    Phase Distribution2 total trials
    Phase 2/3Combined phases
    2(100.0%)

    Highest Phase Reached

    Phase 2/3

    Trial Status & Enrollment

    Completion Rate

    66.7%

    2 of 3 finished

    Non-Completion Rate

    33.3%

    1 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Completed(2)
    Terminated(1)

    Detailed Status

    Completed2
    Withdrawn1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 2/3

    Trials by Phase

    Phase 2/32 (100.0%)

    Trials by Status

    withdrawn133%
    completed267%

    Recent Activity

    0 active trials
    Showing 3 of 3
    completedphase_2_3

    Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas

    NCT00443196
    withdrawn

    Demographics, Clinical Outcomes, and Physician Attitudes in Patients Who Have Received The MiCK Assay (CorrectChemo)

    NCT02137811
    completedphase_2_3

    Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis

    NCT00243685

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT00443196Phase 2/3

    Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas

    Completed
    NCT02137811

    Demographics, Clinical Outcomes, and Physician Attitudes in Patients Who Have Received The MiCK Assay (CorrectChemo)

    Withdrawn
    NCT00243685Phase 2/3

    Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis

    Completed

    All 3 trials loaded

    Drug Details

    Intervention Type
    Varies by study
    Total Trials
    3